These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31452337)

  • 1. Belatacept-based immunosuppression: A calcineurin inhibitor-sparing regimen in heart transplant recipients.
    Launay M; Guitard J; Dorent R; Prevot Y; Prion F; Beaumont L; Kably B; Lecuyer L; Billaud EM; Guillemain R
    Am J Transplant; 2020 Feb; 20(2):553-563. PubMed ID: 31452337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of a fusion protein T-cell co-stimulation blocker Belatacept in heart transplant recipients: Real world experience from a high volume center.
    Oren D; Uriel M; Moeller CM; Valledor AF; DeFilippis EM; Lotan D; Colombo PC; Yuzefpolskaya M; Topkara VK; Clerkin KJ; Raikhelkar JK; Fried JA; Oh DKT; Bae D; Lin E; Theodoropoulos K; Naka Y; Takeda K; Choe J; Jennings DL; Majure D; Latif F; Sayer G; Uriel N
    Clin Transplant; 2024 Mar; 38(3):e15251. PubMed ID: 38504576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
    Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
    BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
    Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
    J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
    Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
    Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
    Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
    Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belatacept based immunosuppression: What and when to combine?
    Schilsky J; Dvorai RH; Yang C; Suo L; Saracino G; Shahbazov R
    Transpl Immunol; 2024 Aug; 85():102050. PubMed ID: 38810889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
    Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
    Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
    Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
    Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
    Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
    Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
    Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
    Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
    Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States.
    Karadkhele G; Duneton C; Garro R; Badell IR; Pearson TC; Larsen CP; Hogan J
    Clin Transplant; 2022 Mar; 36(3):e14531. PubMed ID: 34757651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction.
    Gupta G; Regmi A; Kumar D; Posner S; Posner MP; Sharma A; Cotterell A; Bhati CS; Kimball P; Massey HD; King AL
    Am J Transplant; 2015 Oct; 15(10):2726-31. PubMed ID: 25988397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to Belatacept in kidney transplant recipients with chronic antibody-mediated rejection (CAMR).
    Moein M; Gao SX; Martin SJ; Farkouh KM; Li BW; Ball AS; Dvorai RH; Saidi RF
    Transpl Immunol; 2023 Feb; 76():101737. PubMed ID: 36379374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belatacept for maintenance immunosuppression in cardiothoracic transplantation: The potential frontier.
    Ensor CR; Goehring KC; Iasella CJ; Moore CA; Lendermon EA; McDyer JF; Morrell MR; Sciortino CM; Venkataramanan R; Wiland AM
    Clin Transplant; 2018 Oct; 32(10):e13363. PubMed ID: 30058177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol.
    Malvezzi P; Fischman C; Rigault G; Jacob MC; Raskovalova T; Jouve T; Janbon B; Rostaing L; Cravedi P
    Transpl Immunol; 2019 Oct; 56():101207. PubMed ID: 31071442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.